Akero Therapeutics AKRO shares opened at $16.16 Thursday morning after pricing of 5.75 million shares of common stock at $16.
Akero was founded in January 2017 and focuses on developing transformative treatments for serious metabolic diseases with high unmet medical need, with the accent on non-alcoholic steatohepatitis, or NASH, which currently has no FDA-approved therapies.
Akero's lead candidate AKR-001, an analog of fibroblast growth factor 21, or FGF21, is being evaluated for NASH. FGF21 is a hormone that regulates metabolism of lipids, carbohydrates and proteins and also protects tissues from various forms of stress.
Akero reported a wider loss of $81.71 million for the fiscal year 2018 compared to $4.56 million in 2017. For the three months ended March 2019, the company reported a loss of $5.36 million.
The stock traded around $16.71 per share at time of publication.
Related Links:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
